Ono Pharmaceutical Co Ltd (OPHLY) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · United States · ISIN US6827361030
Ono Pharmaceutical Co Ltd financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 486.87 bn JPY | 546.89 bn JPY |
| Gross profit | 338.92 bn JPY | 396.63 bn JPY |
| Operating income | 59.75 bn JPY | 109.57 bn JPY |
| EBIT | 64.65 bn JPY | 109.57 bn JPY |
| Net income | 50.05 bn JPY | 73.97 bn JPY |
| Diluted EPS – continuing operations | 35.51 JPY | 52.47 JPY |
Full history since 2005, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Ono Pharmaceutical Co Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has strategic collaboration with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; Congruence Therapeutics; and Aitia, Inc. for drug discovery of novel therapeutic targets for neurological diseases. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
More stocks
- Impulsora del Desarrollo y el Empleo en América Latina S.A.B. de C.V (IDEALB-1.MX)
- Wuxi Lead Auto Equipment Co Ltd (300450.SZ)
- KakaoBank Corp (323410.KS)
- Petrovietnam Gas JSC (GAS.VN)
- Nice Ltd ADR (NICE)
- Hachijuni Nagano Bank Ltd (8359.T)
- Sinar Mas Multiartha Tbk (SMMA.JK)
- Tianshui Huatian Technology Co Ltd (002185.SZ)
- Horizon Robotics (9660.HK)
- ALS Ltd (ALQ.AX)
- Union Electric Company (UEPEO)
- VALLEY NATIONAL BANCORP (VLY)
Not investment advice. All data without warranty, price as of 19.10.2026. Details in the risk notice.